Zhang Zi-jin, Zhang Ping, Wu Xiao-nan, Li Lin, Cheng Gang
Department of Medical Oncology, Beijing Hospital, Beijing 100730, China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010 Aug;32(4):371-4. doi: 10.3881/j.issn.1000-503X.2010.04.003.
To evaluate the efficacy and progression-free survival of erlotinib after progression of disease to gefitinib in patients with advanced pulmonary adenocarcinoma who previously obtained a disease control with gefitinib.
In this retrospective study, 12 patients with advanced or metastatic pulmonary adenocarcinoma,who were previously obtained a partial response or a stable disease with gefitinib,were treated with erlotinib after gefitinib failure. Erlotinib efficiency, progression-free survival and overall survival were analyzed.
Nice (75%)achieved stable disease and three (25%) achieved progression disease with erlotinib treatment after gefitinib failure. No complete response or partial response was observed. The disease control rate was 75%. The median progression-free survival and overall survival of erlotinib were 180 days and 831 days.
Erlotinib seems to be an optional treatment after gefitinib failure for advanced pulmonary adenocarcinoma patients,who previously responded to gefitinib.
评估既往接受吉非替尼治疗获得疾病控制的晚期肺腺癌患者疾病进展后使用厄洛替尼的疗效和无进展生存期。
在这项回顾性研究中，12例先前接受吉非替尼治疗获得部分缓解或病情稳定的晚期或转移性肺腺癌患者，在吉非替尼治疗失败后接受厄洛替尼治疗。分析厄洛替尼的疗效、无进展生存期和总生存期。
吉非替尼治疗失败后接受厄洛替尼治疗的患者中，9例（75%）病情稳定，3例（25%）病情进展。未观察到完全缓解或部分缓解。疾病控制率为75%。厄洛替尼的中位无进展生存期和总生存期分别为180天和831天。
对于先前对吉非替尼有反应的晚期肺腺癌患者，吉非替尼治疗失败后，厄洛替尼似乎是一种可选的治疗方法。
